Cardiovascular Improvements With MV ASV Therapy in Heart Failure

Inclusion Criteria: * Patients 21 years or older * Patients with prior clinical diagnosis of heart failure (HFrEF or HFpEF), or de novo diagnosis of HFpEF indicated by a local BNP≥300 pg/mL or NT pro-BNP≥1200 pg/mL on admission without systolic blood pressure \>180 mmHg or atrial fibrillation, or diagnosis of HFrEF indicated by documented evidence of prescribed beta-blockers and ACE-inhibitors or ARBs for at least 4 weeks prior to admission * Hospital admission for acute decompensated HF as determined by: * Dyspnea at rest or with minimal exertion * AND At least two of the following signs and symptoms: * Orthopnea * Pulmonary rales beyond basilar * Chest congestion on x-ray * BNP≥300pg/mL or NT pro-BNP≥1200pg/mL * Pulmonary capillary wedge pressure (PCWP) ≥25mmHg during current hospitalization * Presented to hospital or clinic at least 24 hours prior to consent * Patient stable enough to stop oxygen use for duration of polygraphy test or have access to dual lumen cannula for polygraphy test * Sleep disordered breathing (SDB) documented by polygraphy with an AHI≥15 events/hour * Patient is able to fully understand study information and sign a consent form Exclusion Criteria: * Right-sided heart failure without left-sided heart failure * Sustained systolic blood pressure \<80 mmHg at baseline * Acute coronary syndrome within 1 months of randomization * Active myocarditis * Complex congenital heart disease * Constrictive pericarditis * Non-cardiac pulmonary …